Patents Assigned to Intellect Neurosciences Inc.
-
Publication number: 20140294724Abstract: This invention relates to antibody drug conjugates and methods of use thereof. More particularly, antibody drug conjugates comprising a cytoprotective agent are provided, wherein the conjugates are useful for the treatment of proteinopathies such as Alzheimer's disease.Type: ApplicationFiled: October 24, 2012Publication date: October 2, 2014Applicant: INTELLECT NEUROSCIENCES, INC.Inventor: Daniel G. Chain
-
Patent number: 8703137Abstract: The invention is directed to methods of treatment of Alzheimer's disease and other tauopathies, via the administration of antibodies having specificity to abnormal forms of tau protein, the antibodies showing no binding and/or reactivity to a normal tau protein and being administered under conditions and in amounts effective to prevent or treat Alzheimer's disease or other tauopathies. In certain embodiments, the antibodies are selective for soluble truncated tau protein truncated at (i) its C-terminus after the glutamic acid residue Glu391, or (ii) at the aspartic acid residue Asp421, or (iii) at its N-terminus at the aspartic acid residue Asp13, or (iv) a combination of (i)-(iii). Further aspects of the invention are directed to the administration of an immunogen comprising an abnormal tau, preferably a soluble truncated tau.Type: GrantFiled: January 31, 2012Date of Patent: April 22, 2014Assignee: Intellect Neurosciences Inc.Inventor: Daniel G. Chain
-
Patent number: 8697076Abstract: Antibodies selective for pathological tau dimers and/or prefibrillar pathological tau oligomers, immunogenic peptides and epitopes of these antibodies, hydridomas producing these antibodies, uses of these antibodies, immunogenic peptides and epitopes in preparation of pharmaceutical compositions for the treatment of tauopathies, and uses of these antibodies, immunogenic peptides, epitopes and pharmaceutical compositions in the treatment of tauopathies are described. Also described are uses of these antibodies, immunogenic peptides, epitopes in diagnosis and monitoring of tauopathies.Type: GrantFiled: April 27, 2012Date of Patent: April 15, 2014Assignees: Northwestern University, Intellect Neurosciences Inc.Inventors: Lester I. Binder, Daniel G. Chain, Yifan Fu, Kristina Patterson
-
Patent number: 8338379Abstract: An antibody capable of recognizing amyloid ? while not recognizing amyloid ? precursor proteins, and a method for using the same. A monoclonal antibody characterized by being capable of recognizing the N-terminus peptide of amyloid ? while not recognizing amyloid ? precursor proteins, an amyloid ? assay kit, a therapeutic agent of Alzheimer's disease, and a method for treating Alzheimer's disease using the monoclonal antibody.Type: GrantFiled: September 23, 2010Date of Patent: December 25, 2012Assignee: Intellect Neurosciences, Inc.Inventors: Haruyasu Yamaguchi, Noriaki Kinoshita, Masahiro Maeda, Yuko Horikoshi
-
Publication number: 20120244159Abstract: The invention relates to methods of treating a subject having Alzheimer's Disease, comprising the step of administering an antibody molecule which is targeted to ? amyloid peptide or to fragment thereof. In another embodiment the invention relates to methods of treating a disease or a disorder, characterized by amyloid beta deposition. In another embodiment, the invention relates to an antibody molecule, which is free end-specific for the N-terminus or the C-terminus of an amyloid ? peptide and to a pharmaceutical composition thereof. In another embodiment, the invention relates to an antibody molecule, which is targeted to the free C or N-terminus of a N- and/or C-terminus truncated amyloid ? peptide fragment.Type: ApplicationFiled: April 12, 2012Publication date: September 27, 2012Applicant: INTELLECT NEUROSCIENCES INC.Inventor: Daniel G. Chain
-
Patent number: 8173127Abstract: The invention relates to methods of treating a subject having Alzheimer's Disease, comprising the step of administering an antibody molecule which is targeted to ? amyloid peptide or to fragment thereof. In another embodiment the invention relates to methods of treating a disease or a disorder, characterized by amyloid beta deposition. In another embodiment, the invention relates to an antibody molecule, which is free end-specific for the N-terminus or the C-terminus of an amyloid ? peptide and to a pharmaceutical composition thereof. In another embodiment, the invention relates to an antibody molecule, which is targeted to the free C or N-terminus of a N-and/or C-terminus truncated amyloid ? peptide fragment.Type: GrantFiled: February 28, 2002Date of Patent: May 8, 2012Assignee: Intellect Neurosciences, Inc.Inventor: Daniel G. Chain
-
Publication number: 20120095071Abstract: Substantially pure 3-(3-indolyl)propionic acid free acid is synthesized by converting the free acid to 3-(3-indolyl)propionic acid calcium salt (3-IPA calcium), precipitating and washing, and then reconverting the 3-IPA calcium to the free acid. 3-IPA calcium is suitable for use in pharmaceutical compositions in tablet and sustained-release dosage forms. 3-IPA calcium can be used to inhibit the cytotoxic effects of amyloid beta protein on cells, to treat fibrillogenic diseases in a mammal, and to treat diseases or conditions in which free radicals or oxidative stress plays a role.Type: ApplicationFiled: May 24, 2011Publication date: April 19, 2012Applicant: INTELLECT NEUROSCIENCES INC.Inventor: Norman H. Rogers
-
Publication number: 20110280879Abstract: The invention provides a chimeric peptide or mixture of chimeric peptides that can be formulated as an immunizing composition and used in a method for immunization of a mammal against an internal peptide cleavage product derived from a precursor or mature protein, for which the peptide cleavage product and the precursor or mature protein are self molecules. The chimeric peptide or peptides have an end-specific B cell epitope from a naturally-occurring internal peptide cleavage product of a precursor or mature protein, as a free N- or C-terminus, fused with or without spacer residues to a T helper cell epitope derived from a living source different from that of the internal peptide cleavage product.Type: ApplicationFiled: November 22, 2010Publication date: November 17, 2011Applicant: INTELLECT NEUROSCIENCES, INC.Inventor: Benjamin Chain
-
Patent number: 7901689Abstract: The invention provides a chimeric peptide or mixture of chimeric peptides that can be formulated as an immunizing composition and used in a method for immunization of a mammal against an internal peptide cleavage product derived from a precursor or mature protein, for which the peptide cleavage product and the precursor or mature protein are self molecules. The chimeric peptide or peptides have an end-specific B cell epitope from a naturally-occurring internal peptide cleavage product of a precursor or mature protein, as a free N- or C-terminus, fused with or without spacer residues to a T helper cell epitope derived from a living source different from that of the internal peptide cleavage product.Type: GrantFiled: December 8, 2000Date of Patent: March 8, 2011Assignee: Intellect Neurosciences, Inc.Inventor: Benjamin Chain
-
Publication number: 20110027279Abstract: DNA encoding a recombinant antibody molecule end-specific for an amyloid-beta peptide, pharmaceutical compositions thereof, and a method for preventing or inhibiting progression of Alzheimer's Disease by introducing such a DNA molecule into brain cells to express the recombinant antibody molecule and prevent the accumulation of amyloid-beta peptides in the cerebrospinal fluid.Type: ApplicationFiled: January 21, 2010Publication date: February 3, 2011Applicant: INTELLECT NEUROSCIENCES INC.Inventor: Daniel G. Chain
-
Publication number: 20110008339Abstract: An antibody capable of recognizing amyloid ? while not recognizing amyloid ? precursor proteins, and a method for using the same. A monoclonal antibody characterized by being capable of recognizing the N-terminus peptide of amyloid ? while not recognizing amyloid ? precursor proteins, an amyloid ? assay kit, a therapeutic agent of Alzheimer's disease, and a method for treating Alzheimer's disease using the monoclonal antibody.Type: ApplicationFiled: September 23, 2010Publication date: January 13, 2011Applicant: INTELLECT NEUROSCIENCES INC.Inventors: Haruyasu Yamaguchi, Noriaki Kinoshita, Masahiro Maeda, Yuko Horikoshi
-
Publication number: 20100317710Abstract: Substantially pure 3-(3-indolyl)propionic acid free acid is synthesized by converting the free acid to 3-(3-indolyl)propionic acid calcium salt (3-IPA calcium), precipitating and washing, and then reconverting the 3-IPA calcium to the free acid. 3-IPA calcium is suitable for use in pharmaceutical compositions in tablet and sustained-release dosage forms. 3-IPA calcium can be used to inhibit the cytotoxic effects of amyloid beta protein on cells, to treat fibrillogenic diseases in a mammal, and to treat diseases or conditions in which free radicals or oxidative stress plays a role.Type: ApplicationFiled: January 21, 2010Publication date: December 16, 2010Applicant: INTELLECT NEUROSCIENCES INC.Inventor: Norman H. Rogers
-
Patent number: 7807157Abstract: An antibody capable of recognizing amyloid ? while not recognizing amyloid ? precursor proteins, and a method for using the same. A monoclonal antibody characterized by being capable of recognizing the N-terminus peptide of amyloid ? while not recognizing amyloid ? precursor proteins, an amyloid ? assay kit, a therapeutic agent of Alzheimer's disease, and a method for treating Alzheimer's disease using the monoclonal antibody.Type: GrantFiled: September 16, 2004Date of Patent: October 5, 2010Assignee: Intellect Neurosciences Inc.Inventors: Haruyasu Yamaguchi, Noriaki Kinoshita, Masahiro Maeda, Yuko Horikoshi
-
Publication number: 20090069258Abstract: DNA encoding a recombinant antibody molecule end-specific for an amyloid-beta peptide, pharmaceutical compositions thereof, and a method for preventing or inhibiting progression of Alzheimer's Disease by introducing such a DNA molecule into brain cells to express the recombinant antibody molecule and prevent the accumulation of amyloid-beta peptides in the cerebrospinal fluid.Type: ApplicationFiled: May 8, 2007Publication date: March 12, 2009Applicant: Intellect Neurosciences Inc.Inventor: Daniel G. Chain
-
Publication number: 20080207731Abstract: Substantially pure 3-(3-indolyl)propionic acid free acid is synthesized by converting the free acid to 3-(3-indolyl)propionic acid calcium salt (3-IPA calcium), precipitating and washing, and then reconverting the 3-IPA calcium to the free acid. 3-IPA calcium is suitable for use in pharmaceutical compositions in tablet and sustained-release dosage forms. 3-IPA calcium can be used to inhibit the cytotoxic effects of amyloid beta protein on cells, to treat fibrillogenic diseases in a mammal, and to treat diseases or conditions in which free radicals or oxidative stress plays a role.Type: ApplicationFiled: August 23, 2007Publication date: August 28, 2008Applicant: Intellect Neurosciences, Inc.Inventor: Norman H. Rogers